MCID: PRP003
MIFTS: 64

Porphyria Cutanea Tarda malady

Categories: Genetic diseases, Rare diseases, Metabolic diseases, Eye diseases, Nephrological diseases, Skin diseases, Liver diseases

Aliases & Classifications for Porphyria Cutanea Tarda

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 23GeneReviews, 24GeneTests, 27GTR, 30ICD10, 31ICD10 via Orphanet, 37MedGen, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 50Novoseek, 52OMIM, 54Orphanet, 62SNOMED-CT, 64The Human Phenotype Ontology, 68UMLS, 69UMLS via Orphanet, 70UniProtKB/Swiss-Prot, 71Wikipedia
See all MalaCards sources

Aliases & Descriptions for Porphyria Cutanea Tarda:

Name: Porphyria Cutanea Tarda 52 11 71 48 54 27 12 50 39 13 68
Hepatoerythropoietic Porphyria 11 71 23 48 24 54 70 27 13 68
Familial Porphyria Cutanea Tarda 54 70 68
Hep 48 54 70
Uroporphyrinogen Decarboxylase Deficiency 70 68
Porphyria, Hepatoerythropoietic 52 39
Porphyria Cutanea Tarda Type Ii 54 70
 
Pct 71 54
Porphyria Hepatocutaneous Type 70
Porphyria, Hepatic 48
Porphyria Hepatic 50
Urod Deficiency 70
Pct Type Ii 70
Fpct 70

Characteristics:

Orphanet epidemiological data:

54
hepatoerythropoietic porphyria:
Inheritance: Autosomal recessive; Prevalence: <1/1000000 (Worldwide)
porphyria cutanea tarda:
Inheritance: Autosomal dominant,Multigenic/multifactorial; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe); Age of onset: Adult; Age of death: normal life expectancy
familial porphyria cutanea tarda:
Inheritance: Autosomal dominant

HPO:

64
porphyria cutanea tarda:
Inheritance: autosomal dominant inheritance

Classifications:



External Ids:

OMIM52 176100
Disease Ontology11 DOID:3132, DOID:5230
ICD1030 E80.1
SNOMED-CT62 61860000, 111386004
ICD10 via Orphanet31 E80.1, E80.2
MESH via Orphanet40 D017121, D017119
UMLS via Orphanet69 C0162569, C0268324, C0162566

Summaries for Porphyria Cutanea Tarda

About this section
UniProtKB/Swiss-Prot:70 Familial porphyria cutanea tarda: A form of porphyria. Porphyrias are inherited defects in the biosynthesis of heme, resulting in the accumulation and increased excretion of porphyrins or porphyrin precursors. They are classified as erythropoietic or hepatic, depending on whether the enzyme deficiency occurs in red blood cells or in the liver. Familial porphyria cutanea tarda is an autosomal dominant disorder characterized by light-sensitive dermatitis, with onset in later life. It is associated with the excretion of large amounts of uroporphyrin in the urine. Iron overload is often present in association with varying degrees of liver damage. Hepatoerythropoietic porphyria: A form of porphyria. Porphyrias are inherited defects in the biosynthesis of heme, resulting in the accumulation and increased excretion of porphyrins or porphyrin precursors. They are classified as erythropoietic or hepatic, depending on whether the enzyme deficiency occurs in red blood cells or in the liver. HEP is a cutaneous porphyria that presents in infancy. It is characterized biochemically by excessive excretion of acetate-substituted porphyrins and accumulation of protoporphyrin in erythrocytes. Uroporphyrinogen decarboxylase levels are very low in erythrocytes and cultured skin fibroblasts.

MalaCards based summary: Porphyria Cutanea Tarda, also known as hepatoerythropoietic porphyria, is related to coproporphyria and porphyria variegata, and has symptoms including thin skin, cutaneous photosensitivity and hemolytic anemia. An important gene associated with Porphyria Cutanea Tarda is UROD (Uroporphyrinogen Decarboxylase), and among its related pathways are HIF-1-alpha transcription factor network and Iron metabolism in placenta. The drugs hydroxychloroquine and hydroxychloroquine sulfate have been mentioned in the context of this disorder. Affiliated tissues include skin, liver and eye, and related mouse phenotypes are liver/biliary system and homeostasis/metabolism.

Disease Ontology:11 An acute porphyria characterized by painful, blistering skin lesions that develop on sun-exposed skin.

NIH Rare Diseases:48 Hepatoerythropoietic porphyria (HEP) is an inherited cutaneous porphyria caused by a deficiency of the enzyme uroporphyrinogen decarboxylase. It is the autosomal recessive form of familial Porphyria Cutanea Tarda (f-PCT). The manifestations of HEP resemble Congenital Erythropoietic Porphyria (CEP), with symptoms of skin blistering that usually begin in infancy. Treatment may include scheduled phlebotomy and low dose hydroxychloroquine. Last updated: 10/26/2010

OMIM:52 Porphyria cutanea tarda (PCT) is characterized by light-sensitive dermatitis and the excretion of large amounts of... (176100) more...

Wikipedia:71 Porphyria cutanea tarda (PCT) is the most common subtype of porphyria. The disease is named because it... more...

GeneReviews for NBK169003

Related Diseases for Porphyria Cutanea Tarda

About this section

Diseases in the Porphyria Cutanea Tarda family:

Porphyria Cutanea Tarda, Type I Familial Porphyria Cutanea Tarda

Diseases related to Porphyria Cutanea Tarda via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 125)
idRelated DiseaseScoreTop Affiliating Genes
1coproporphyria29.2ALAD, CPOX, FECH, HMBS, PPOX, UROD
2porphyria variegata26.4ALAD, CPOX, FECH, HFE, HMBS, PPOX
3porphyria cutanea tarda, type i12.7
4familial porphyria cutanea tarda12.5
5porphyria, acute intermittent11.4
6porphyria11.3
7urod-related porphyrias11.1
8hepatitis10.9
9hepatitis c10.9
10hepatitis c virus10.7
11hemochromatosis10.7
12lupus erythematosus10.5
13dermatoosteolysis, kirghizian type10.4HFE, TF
14leukemia10.4
15systemic lupus erythematosus10.3
16hemophagocytic reticulosis10.3HAMP, HFE2
17thbd-related atypical hemolytic-uremic syndrome10.3HAMP, HFE
18hereditary multiple osteochondromas10.3HFE, HFE2
19liver disease10.3
20malignant visceral pleura tumor10.3TF, TFRC
21harp syndrome10.3HFE, TF
22hepatoblastoma10.2
23hepatocellular carcinoma10.2
24cutaneous lupus erythematosus10.2
25siderosis10.2
26viral hepatitis10.2
27subacute cutaneous lupus erythematosus10.2
28basilar artery insufficiency10.2HFE, TFRC
29alopecia10.2
30epidermolysis bullosa10.2
31hypertrichosis10.2
32peritonitis10.2
33discoid lupus erythematosus10.2
34kcnq2-related disorders10.1HAMP, HFE, HFE2
35tongue squamous cell carcinoma10.1HAMP, HFE, TF
36sickle cell anemia10.1HFE, TF, TFRC
37cognitive impairment with or without cerebellar ataxia10.1HAMP, TF
38myelodysplastic syndrome10.1
39arthritis10.1
40hepatitis b10.1
41myelofibrosis10.1
42thalassemia10.1
43lymphoma10.1
44lymphoblastic leukemia10.1
45constrictive pericarditis10.1
46cholestasis10.1
47pericarditis10.1
48acute porphyria10.1
49epidermolysis bullosa acquisita10.1
50lichen planus10.1

Graphical network of the top 20 diseases related to Porphyria Cutanea Tarda:



Diseases related to porphyria cutanea tarda

Symptoms & Phenotypes for Porphyria Cutanea Tarda

About this section

Symptoms by clinical synopsis from OMIM:

176100

Clinical features from OMIM:

176100

Human phenotypes related to Porphyria Cutanea Tarda:

 64 54 (show all 27)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 thin skin64 54 hallmark (90%) Very frequent (99-80%) HP:0000963
2 cutaneous photosensitivity64 54 hallmark (90%) Very frequent (99-80%) HP:0000992
3 hemolytic anemia64 54 hallmark (90%) Very frequent (99-80%) HP:0001878
4 skin rash64 54 hallmark (90%) Very frequent (99-80%) HP:0000988
5 hypopigmented skin patches64 54 hallmark (90%) Very frequent (99-80%) HP:0001053
6 irregular hyperpigmentation64 hallmark (90%) HP:0007400
7 abnormal blistering of the skin64 54 hallmark (90%) Very frequent (99-80%) HP:0008066
8 edema64 54 occasional (7.5%) Occasional (29-5%) HP:0000969
9 atypical scarring of skin64 54 occasional (7.5%) Occasional (29-5%) HP:0000987
10 hypertrichosis64 occasional (7.5%) HP:0000998
11 cirrhosis64 54 occasional (7.5%) Occasional (29-5%) HP:0001394
12 hepatic steatosis64 54 occasional (7.5%) Occasional (29-5%) HP:0001397
13 sudden cardiac death64 54 occasional (7.5%) Occasional (29-5%) HP:0001645
14 neoplasm of the liver64 occasional (7.5%) HP:0002896
15 reduced consciousness/confusion64 occasional (7.5%) HP:0004372
16 cerebral palsy64 54 occasional (7.5%) Occasional (29-5%) HP:0100021
17 fragile skin64 HP:0001030
18 hepatocellular carcinoma64 54 Occasional (29-5%) HP:0001402
19 alopecia64 HP:0001596
20 onycholysis64 HP:0001806
21 facial hypertrichosis64 HP:0002219
22 hyperpigmentation in sun-exposed areas64 HP:0005586
23 scleroderma64 HP:0100324
24 hyperpigmentation of the skin54 Very frequent (99-80%)
25 generalized hirsutism54 Occasional (29-5%)
26 erythema54 Very frequent (99-80%)
27 skin vesicle54 Very frequent (99-80%)

MGI Mouse Phenotypes related to Porphyria Cutanea Tarda according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053708.2CYP1A2, FECH, HFE, HFE2, TFRC, UROD
2MP:00053767.2CYP1A2, FECH, HFE, HFE2, HMBS, PPOX
3MP:00107686.4CYP1A2, FECH, HFE, HFE2, HMBS, PPOX

Drugs & Therapeutics for Porphyria Cutanea Tarda

About this section

Drugs for Porphyria Cutanea Tarda (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 43)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
IronapprovedPhase 3, Phase 211237439-89-623925
Synonyms:
02583_FLUKA
12310_ALDRICH
12310_RIEDEL
129048-51-7
14067-02-8
161135-39-3
190454-13-8
195161-83-2
199281-22-6
209309_ALDRICH
209309_SIAL
255637_ALDRICH
266213_ALDRICH
266256_ALDRICH
267945_ALDRICH
267953_ALDRICH
26Fe
338141_ALDRICH
356808_ALDRICH
356824_ALDRICH
356832_ALDRICH
39344-71-3
3ZhP
413054_ALDRICH
443783-52-6
44890_ALDRICH
44890_FLUKA
675141-17-0
70884-35-4
73135-38-3
7439-89-6
8011-79-8
8053-60-9
AC1L2N38
ATW 230
ATW 432
Ancor B
Ancor en 80/150
Armco iron
Atomel 28
Atomel 300M200
Atomel 500M
Atomel 95
Atomiron 44MR
Atomiron 5M
Atomiron AFP 25
Atomiron AFP 5
C00023
C3518_SIAL
C3518_SIGMA
CCRIS 1580
CHEBI:18248
CID23925
Carbonyl iron
Copy Powder CS 105-175
D007501
DB01592
DSP 1000
DSP 128B
DSP 135
DSP 135C
DSP 138
Diseases (animal), iron overload
Diseases, iron overload
EF 1000
EF 250
EFV 200/300
EFV 250
EFV 250/400
EINECS 231-096-4
 
Ed-In-Sol
Eisen
Electrolytic iron
F 60 (metal)
FE
FT 3 (element)
Fe
Fe-40
Fe1+
Feronate
Ferretts
Ferro-Caps
Ferro-Time
Ferrousal
Ferrovac E
Ferrum
Ferrum metallicum
GS 6
HF 2 (element)
HL (iron)
HQ (metal)
HS (iron)
HS 4849
HSDB 604
Hemocyte
Hierro
Hoeganaes ATW 230
Hoeganaes EH
IRMM524A_FLUKA
IRMM524B_FLUKA
IRON
Iron (Fe)
Iron (Fe1+)
Iron ion (Fe+)
Iron ion(1+)
Iron monocation
Iron powder
Iron standard for AAS
Iron(1+)
Iron(1+) ion
Iron(III) nitrate solution
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (Fe1+)
Iron, ion (Fe1+) (8CI,9CI)
Iron, reduced
LOHA
LS-3196
MolPort-003-925-001
NC 100
PZh-1M3
PZh-2
PZh1M1
PZh2M
PZh2M1
PZh2M2
PZh3
PZh3M
PZh4M
PZhO
Reduced iron
Remko
SUY-B 2
Siderol
UNII-E1UOL152H7
Vitedyn-Slo
Yieronia
fer
ferrous iron
hierro
2
Deferasiroxapproved, investigationalPhase 3, Phase 289201530-41-85493381
Synonyms:
Deferasiroxum
Deferasiroxum [inn-latin]
 
Exjade
ICL 670
ICL 670a
deferasirox
3
ColestipolapprovedPhase 2, Phase 3626658-42-4, 50925-79-662816
Synonyms:
Colestipolum
 
Colestipolum [INN-Latin]
Copolymer of bis(2-aminoethyl)amine and 2-(chloromethyl)oxirane
Epichlorohydrin-tetraethylenepentamine polymer
4alpha-MSHPhase 3, Phase 214
5Iron Chelating AgentsPhase 3, Phase 2222
6Hormone AntagonistsPhase 3, Phase 212778
7Chelating AgentsPhase 3, Phase 21365
8HormonesPhase 3, Phase 213979
9Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 3, Phase 212767
10Lipid Regulating AgentsPhase 2, Phase 32702
11Hypolipidemic AgentsPhase 2, Phase 32721
12AntimetabolitesPhase 2, Phase 311774
13cysteineNutraceuticalPhase 3190
14
HydroxychloroquineapprovedPhase 2146118-42-33652
Synonyms:
(+-)-Hydroxychloroquine
(±)-hydroxychloroquine
118-42-3
2-((4-((7-Chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol
2-((4-((7-chloro-4-Quinolyl)amino)pentyl)ethylamino)ethanol
2-(N-(4-(7-Chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol
2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol
2-[{4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino]ethanol
5-22-10-00280 (Beilstein Handbook Reference)
7-Chloro-4-(4-(N-ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino)quinoline
7-Chloro-4-(4-(ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline
7-Chloro-4-(5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl)aminoquinoline
7-chloro-4-(4-(Ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline
7-chloro-4-(4-(N-Ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino)quinoline
7-chloro-4-[4-(N-Ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino]quinoline
7-chloro-4-[5-(N-Ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline
747-36-4 (sulfate (1:1) salt)
AC1L1GEW
BRN 0253894
C07043
C18H26ClN3O
CHEMBL1535
CID3652
D08050
DB01611
DivK1c_000942
EINECS 204-249-8
Gen-Hydroxychloroquine 200mg Tablets
HCQ
HMS502P04
Hidroxicloroquina
 
Hidroxicloroquina [INN-Spanish]
Hydroxychlorochin
Hydroxychloroguine
Hydroxychloroquine (INN)
Hydroxychloroquine Sulfate (1:1) Salt
Hydroxychloroquine [INN:BAN]
Hydroxychloroquinum
Hydroxychloroquinum [INN-Latin]
IDI1_000942
Idrossiclorochina
Idrossiclorochina [DCIT]
KBio1_000942
LS-66614
MolPort-003-847-792
NCGC00159483-02
NINDS_000942
NSC4375
Oxichlorochine
Oxichlorochinum
Oxichloroquine
Oxychlorochin
Oxychloroquine
PlaqueN/A
Polirreumin
Polirreumin (TN)
Quensyl
SPBio_001116
ST072188
Spectrum2_001238
Spectrum5_001697
UNII-4QWG6N8QKH
WIN 1258
hydroxychloroquine
15Antirheumatic AgentsPhase 210627
16Antiprotozoal AgentsPhase 21986
17Anti-Infective AgentsPhase 221402
18Antiparasitic AgentsPhase 22127
19AntimalarialsPhase 21216
20
DopamineapprovedPhase 1375951-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
21
Chlorpromazineapproved, vet_approvedPhase 11750-53-32726
Synonyms:
10-(3-Dimethylaminopropyl)-2-chlorophenothiazine
10H-Phenothiazine-10-propanamine, 2-chloro-N,N-dimethyl-, radical ion(1+)
2-Chloro-10-(3-(dimethylamino)propyl)phenothiazine
2-Chloro-10-[3-(dimethylamino)propyl]phenothiazine
2-Chloropromazine
2-Cloro-10 (3-dimetilaminopropil)fenotiazina
2-Cloro-10 (3-dimetilaminopropil)fenotiazina [Italian]
2-chloro-10-(3-(dimethylamino)propyl)-phenothiazine
2-chloro-N,N-dimethyl-10H-Phenothiazine-10-propanamine
2601A
3-(2-Chloro-10H-phenothiazin-10-yl)-N,N-dimethyl-1-propanamine
3-(2-Chlorophenothiazin-10-yl)-N,N-dimethyl-propan-1-amine
3-(2-chloro-10H-Phenothiazin-10-yl)-N,N-dimethyl-1-propanamine
3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-amine
3-(2-chlorophenothiazin-10-yl)-N,N-dimethyl-propan-1-amine
3-(2-chlorophenothiazin-10-yl)-N,N-dimethylpropan-1-amine
34468-21-8
4560 R.P
4560 R.P.
4560 Rp hydrochloride
50-53-3
AB00051943
AC1L1EBT
AKOS001490972
Aminasine
Aminazin
Aminazine
Ampliactil
Amplicitil
Amplictil
BAS 00010434
BC 135
BPBio1_000273
BPBio1_001181
BSPBio_000247
BSPBio_002011
Bio1_000457
Bio1_000946
Bio1_001435
Biomol-NT_000020
C06906
C17H19ClN2S
CAS-69-09-0
CCRIS 3711
CHEBI:3647
CHEMBL71
CID2726
CPZ
Chlor-PZ
Chlor-Promanyl
Chlordelazine
Chlorderazin
Chloro-3 (dimethylamino-3 propyl)-10 phenothiazine
Chloro-3 (dimethylamino-3 propyl)-10 phenothiazine [French]
Chloropromazine
Chlorpromados
Chlorpromanyl
Chlorpromanyl (discontinued)
Chlorpromanyl-20
Chlorpromanyl-40
Chlorpromazin
Chlorpromazine
Chlorpromazine (USP/INN)
Chlorpromazine Hydrochloride Intensol
Chlorpromazine Tannate
Chlorpromazine [USAN:INN:BAN]
Chlorpromazinum
Chlorpromazinum [INN-Latin]
Clorpromazina
Clorpromazina [INN-Spanish]
Clorpromazina [Italian]
Contomin
Cromedazine
D00270
DB00477
DivK1c_000624
EINECS 200-045-8
Elmarin
Esmind
Fenactil
Fenaktyl
Fraction AB
HL 5746
HMS1920M03
HMS2089C12
HMS2091E06
HMS501P06
HSDB 3033
 
I14-6226
IDI1_000624
JHICC02042
KBio1_000624
KBio2_000622
KBio2_002312
KBio2_003190
KBio2_004880
KBio2_005758
KBio2_007448
KBio3_001231
KBio3_002792
KBioGR_000806
KBioGR_002312
KBioSS_000622
KBioSS_002314
L000182
LS-105361
Largactil
Largactil Liquid
Largactil Oral Drops
Largactilothiazine
Largactyl
Lopac-C-8138
Lopac0_000249
Megaphen
MolPort-001-727-953
N-(3-Dimethylaminopropyl)-3-chlorophenothiazine
NCGC00015273-01
NCGC00015273-02
NCGC00015273-03
NCGC00015273-14
NCGC00024409-04
NCGC00024409-05
NCGC00024409-06
NCGC00024409-07
NCGC00024409-08
NINDS_000624
NSC 167745
NSC167745
NSC17479
Novo-Chlorpromazine
Novomazina
Oprea1_110255
Phenactyl
Phenathyl
Phenothiazine hydrochloride
Plegomasine
Plegomazin
Prazilpromactil
Prestwick0_000064
Prestwick1_000064
Prestwick2_000064
Prestwick3_000064
Proma
Promactil
Promazil
Propaphen
Propaphenin
Prozil
Psychozine
QTL1_000021
SKF 2601-A
SKF 2601A
SKF-2601
SPBio_001111
SPBio_002168
SPECTRUM1500184
SR-01000000012-5
STK182870
STOCK1S-46588
Sanopron
Spectrum2_001156
Spectrum3_000346
Spectrum4_000283
Spectrum5_000717
Spectrum_000142
Thorazine
Thorazine (TN)
Thorazine Spansule
Thorazine Suppositories
Thorazine hydrochloride
Torazina
UNII-U42B7VYA4P
WLN: T C666 BN ISJ B3N1&1 EG
Wintermin
Z80
[3-(2-Chloro-phenothiazin-10-yl)-propyl]-dimethyl-amine
cMAP_000017
chlorpromazine
22Gastrointestinal AgentsPhase 18109
23Neurotransmitter AgentsPhase 117734
24Dopamine AntagonistsPhase 11083
25Tranquilizing AgentsPhase 14164
26Psychotropic DrugsPhase 16279
27Peripheral Nervous System AgentsPhase 122776
28Antipsychotic AgentsPhase 12359
29Dopamine AgentsPhase 13759
30AntiemeticsPhase 13888
31Liver ExtractsPhase 13868
32Central Nervous System DepressantsPhase 112806
33Autonomic AgentsPhase 19774
34
Aminolevulinic acidapproved157106-60-5137
Synonyms:
106-60-5
35BEC718-C970-426A-9859-BF58284C60B4
5-ALA
5-Amino-4-oxo-Pentanoate
5-Amino-4-oxo-Pentanoic acid
5-Amino-4-oxopentanoate
5-Amino-4-oxopentanoic acid
5-Amino-4-oxovalerate
5-Amino-4-oxovaleric acid
5-Amino-Levulinate
5-Amino-Levulinic acid
5-Aminolaevulinate
5-Aminolaevulinic acid
5-Aminolevulinate
5-Aminolevulinic acid
5-amino-levulinate
5451-09-2
AC-054
AC1L18K9
AKOS003587520
ALA
ALA-PDT
Aladerm
Amino-levulinic acid
Aminolevulinate
Aminolevulinic
Aminolevulinic acid
BIDD:GT0260
BSPBio_003407
C00430
CCRIS 8958
CHEBI:17549
CHEMBL601
CID137
CPD000857229
 
D07567
DALA
DB00855
DivK1c_006954
EINECS 203-414-1
I14-10101
KBio1_001898
KBio2_002062
KBio2_004630
KBio2_007198
KBio3_002627
KBioGR_001176
KBioSS_002062
Kerastick
LMFA01100055
LS-101793
Levulinic acid, 5-amino- (8CI)
MLS001333097
MLS001333098
MolPort-001-788-423
NCGC00178086-01
Pentanoic acid, 5-amino-4-oxo- (9CI)
SAM002589919
SMR000857229
SPBio_001843
ST50819610
SpecPlus_000858
Spectrum2_001662
Spectrum3_001654
Spectrum4_000618
Spectrum5_001505
Spectrum_001582
UNII-88755TAZ87
delta-ALA
delta-Aminolevulinate
delta-Aminolevulinic acid
delta-aminolevulinic acid
35
Isoniazidapproved15054-85-33767
Synonyms:
37271-10-6
4-pyridinecarbohydrazide
41466-07-3
5015 R.P
5015 R.P.
5015 RP
54-85-3
62229-51-0
7640-37-1
AB00052025
AC1L1GNZ
AC1Q54UP
AC1Q54UQ
AI3-23936
AKOS000119062
AZT + Isoniazid
Abdizide
Andrazide
Anidrasona
Antimicina
Antituberkulosum
Armacide
Armazid
Armazide
Atcotibine
Azuren
BB_SC-6246
BIDD:GT0140
BP 5015
BPBio1_000025
BPBio1_001322
BSPBio_000021
BSPBio_002204
Bacillin
Biomol-NT_000288
C07054
C6H7N3O
CAS-54-85-3
CCRIS 351
CHEBI:6030
CHEMBL64
CID3767
CPD000059082
Cedin
Cedin (Aerosol)
Cemidon
Chemiazid
Chemidon
Continazine
Cortinazine
Cotinazin
Cotinizin
D00346
D007538
DB00951
Defonin
Dibutin
Diforin
Dinacrin
Ditubin
DivK1c_000070
Dow-Isoniazid
EINECS 200-214-6
Ebidene
Eralon
Ertuban
Eutizon
Evalon
FRS-3
FSR 3
FSR-3
Fetefu
Fimalene
GINK
HIA
HMS1568B03
HMS1920H09
HMS2089I16
HMS2091N19
HMS500D12
HSDB 1647
Hid rasonil
Hidranizil
Hidrasonil
Hidrulta
Hidrun
Hycozid
Hydra
Hydrazid
Hydrazide
Hyozid
Hyzyd
I.A.I
I.A.I.
I0138
I14-9731
I3377_FLUKA
I3377_SIGMA
IDI1_000070
INH
INHd20
Ido-tebin
Idrazil
In-73
Inah
Inh-Burgthal
Inizid
Iscotin
Isidrina
Ismazide
Isobicina
Isocid
Isocidene
Isocotin
Isohydrazide
Isokin
Isolyn
Isonerit
Isonex
Isoniacid
Isoniazid
Isoniazid & EEP
Isoniazid & Propolis
Isoniazid SA
Isoniazida
Isoniazide
Isoniazidum
Isonicazide
Isonicid
Isonico
Isonicotan
Isonicotil
Isonicotinhydrazid
Isonicotinic acid hydrazide
Isonicotinic hydrazide
Isonicotinohydrazide
Isonicotinoyl hydrazide
Isonicotinoylhydrazide
Isonicotinsaeurehydrazid
Isonicotinyl hydrazide
Isonicotinyl hydrazine
Isonicotinylhydrazine
Isonide
Isonidrin
Isonikazid
Isonilex
Isonin
Isonindon
Isonirit
Isoniton
Isonizida
Isonizide
Isopyrin
 
Isotamine
Isotebe
Isotebezid
Isotinyl
Isozid
Isozide
Isozyd
KBio1_000070
KBio2_001333
KBio2_003901
KBio2_006469
KBio3_001424
KBioGR_000423
KBioSS_001333
L 1945
LANIZID
LS-205
Laniazid
Laniazid (TN)
Laniozid
MLS000069444
MLS001055327
MolPort-000-141-557
Mybasan
NCGC00016244-01
NCGC00016244-02
NCGC00022648-03
NCGC00022648-04
NCGC00022648-05
NCGC00022648-06
NINDS_000070
NSC 9659
NSC9659
Neo-Tizide
Neoteben
Neoxin
Neumandin
Nevin
Niadrin
Nicazide
Nicetal
Nicizina
Niconyl
Nicotibina
Nicotibine
Nicotisan
Nicozide
Nidaton
Nidrazid
Nikozid
Niplen
Nitadon
Niteban
Nitebannsc 9659
Nydrazid
Nyscozid
Oprea1_396155
Pelazid
Percin
Phthisen
Preparation 6424
Prestwick0_000161
Prestwick1_000161
Prestwick2_000161
Prestwick3_000161
Prestwick_578
Pycazide
Pyreazid
Pyricidin
Pyridicin
Pyridine-4-carboxylic acid hydrazide
Pyrizidin
RP 5015
RP-5015
RU-EF-Tb
RY-EF-Tb
Raumanon
Razide
Retozide
Rifamate
Rimicid
Rimifon
Rimiphone
Rimitsid
Robiselin
Robisellin
Roxifen
S1937_Selleck
SAM002554904
SMR000059082
SPBio_000094
SPBio_001942
SPECTRUM1500355
STK086288
Sanohidrazina
Sauterazid
Sauterzid
Spectrum2_000107
Spectrum3_000472
Spectrum4_000022
Spectrum5_000876
Spectrum_000853
Stanozide
TB-Phlogin
TB-Razide
TB-Vis
Tebecid
Tebenic
Tebexin
Tebilon
Tebos
Teebaconin
Tekazin
Tibazide
Tibemid
Tibiazide
Tibinide
Tibison
Tibivis
Tibizide
Tibusan
Tisin
Tisiodrazida
Tizide
Tubazid
Tubazide
Tubeco
Tubecotubercid
Tuberian
Tubicon
Tubilysin
Tubizid
Tubomel
Tyvid
UNII-V83O1VOZ8L
Unicocyde
Unicozyde
Usaf cb-2
Vazadrine
Vederon
WLN: T6NJ DVMZ
ZINC00001590
Zidafimia
Zinadon
Zonazide
bacillen
bp 5 015
isoco tin
isoniazid
isozid e
nchembio884-comp3
nidra zid
rimif on
tebemid
tubercid
36
Protoporphyrin IXexperimental8553-12-8
Synonyms:
3,3'-(3,7,12,17-Tetramethyl-8,13-divinyl-21H,23H-porphine-2,18-diyl)-bis-propionate
3,3'-(3,7,12,17-Tetramethyl-8,13-divinyl-21H,23H-porphine-2,18-diyl)-bis-propionic acid
3,3'-(3,7,12,17-Tetramethyl-8,13-divinylporphine-2,18-diyl)di
Kammerer'S prophyrin
Ooporphyrin
 
Porphyrinogen IX
PpIX
Protoporphyrin
Protoporphyrin IX
Protoporphyrin-"IX"
Protoporphyrin-IX
37Trace Elements5802
38Micronutrients5802
39Photosensitizing Agents476
40Anti-Bacterial Agents10884
41Dermatologic Agents5674
42Antitubercular Agents1272
43Iron SupplementNutraceutical175

Interventional clinical trials:

(show all 29)
idNameStatusNCT IDPhase
1Phase III Confirmatory Study in Erythropoietic ProtoporphyriaUnknown statusNCT01605136Phase 3
2Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea TardaCompletedNCT00599326Phase 3
3Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP)CompletedNCT00979745Phase 3
4Phase III Study of L-Cysteine in Patients With Erythropoietic ProtoporphyriaCompletedNCT00004940Phase 3
5Sorbent Therapy of the Cutaneous PorphyriasCompletedNCT01422915Phase 2, Phase 3
6Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea TardaUnknown statusNCT01284946Phase 2
7Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP)CompletedNCT01097044Phase 2
8Porphozym in the Treatment of Acute Attacks in AIPCompletedNCT00418795Phase 2
9Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea TardaRecruitingNCT01573754Phase 2
10Panhematin for Prevention of Acute Attacks of Porphyria Panhematin for Prevention of Acute Attacks of PorphyriaRecruitingNCT02922413Phase 2
11Controlled Trial of Panhematin in Treatment of Acute Attacks of PorphyriaRecruitingNCT02180412Phase 2
12A Study to Evaluate Long-term Safety and Clinical Activity of ALN-AS1 in Patient With Acute Intermittent Porphyria (AIP)Enrolling by invitationNCT02949830Phase 1, Phase 2
13Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent PorphyriaCompletedNCT02082860Phase 1
14Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine HydrochlorideCompletedNCT02943213Phase 1
15A Phase 1 Study of ALN-AS1 in Patients With Acute Intermittent Porphyria (AIP)RecruitingNCT02452372Phase 1
16Does Exercise and Heat Increase the Lightsensibility in Patients With Erythropoietic ProtoporphyriaUnknown statusNCT00206869
17Risk Factors of Porphyria Cutanea Tarda (PCT)CompletedNCT00213772
18Study of the Pathogenesis of Porphyria Cutanea TardaCompletedNCT00005103
19Study of Cysteine Hydrochloride for Erythropoietic ProtoporphyriaCompletedNCT00004831
20Observational Study of Acute Intermittent Porphyria PatientsCompletedNCT02076763
21Longitudinal Study of the PorphyriasRecruitingNCT01561157
22Oral Iron for Erythropoietic ProtoporphyriasRecruitingNCT02979249
23Erythropoietic Protoporphyrias: Studies of the Natural History, Genotype-Phenotype Correlations, and Psychosocial ImpactRecruitingNCT01688895
24Clinical Diagnosis of Acute PorphyriaRecruitingNCT01568554
25EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)Active, not recruitingNCT02240784
26Mitoferrin-1 Expression in Erythropoietic Protoporphyria (Porphyria Rare Disease Clinical Research Consortium (RDCRC))Active, not recruitingNCT01880983
27Acute Porphyria BiomarkersEnrolling by invitationNCT02935400
28Dental Health, Diet, Inflammation and Biomarkers in Patients With Acute Intermittent Porphyria(AIP)Not yet recruitingNCT01617642
29Effect of Isoniazid on Protoporphyrin Levels in Erythropoietic ProtoporphyriaTerminatedNCT01550705

Search NIH Clinical Center for Porphyria Cutanea Tarda

Inferred drug relations via UMLS68/NDF-RT46:


Cochrane evidence based reviews: porphyria, hepatoerythropoietic

Genetic Tests for Porphyria Cutanea Tarda

About this section

Genetic tests related to Porphyria Cutanea Tarda:

id Genetic test Affiliating Genes
1 Hepatoerythropoietic Porphyria27 24
2 Porphyria Cutanea Tarda27

Anatomical Context for Porphyria Cutanea Tarda

About this section

MalaCards organs/tissues related to Porphyria Cutanea Tarda:

36
Skin, Liver, Eye, Testes, Myeloid, Whole blood, Bone

Publications for Porphyria Cutanea Tarda

About this section

Articles related to Porphyria Cutanea Tarda:

(show top 50)    (show all 564)
idTitleAuthorsYear
1
Illness Perception and Psychological Distress in Persons with Porphyria Cutanea Tarda. (26775575)
2016
2
Resolution of Porphyria Cutanea Tarda in Patients With Hepatitis C Following Ledipasvir-Sofosbuvir Combination Therapy. (27732687)
2016
3
Porphyria cutanea tarda associated with HFE C282Y homozygosity, iron overload, and use of a contraceptive vaginal ring. (26908385)
2016
4
Can curative antivirals benefit porphyria cutanea tarda in hepatitis C patients? (27550066)
2016
5
Porphyria Cutanea Tarda. (27669078)
2016
6
The D519G Polymorphism of Glyceronephosphate O-Acyltransferase Is a Risk Factor for Familial Porphyria Cutanea Tarda. (27661980)
2016
7
Squamous cell carcinoma of the penis successfully treated with imiquimod 5% cream in a porphyria cutanea tarda patient. (27767238)
2016
8
Porphyria cutanea tarda in a HIV- positive patient. (27579753)
2016
9
Human Immunodeficiency Virus Associated Sporadic Nonfamilial Porphyria Cutanea Tarda. (27293254)
2016
10
Human immunodeficiency virus and risk of porphyria cutanea tarda: a possible association examined in a large hospital. (26576928)
2016
11
Porphyria Cutanea Tarda Masquerading as Epidermolysis Bullosa Acquisita: A Report of Two Cases. (26269702)
2015
12
Porphyria cutanea tarda in a child with acute lymphoblastic leukemia. (26319705)
2015
13
Sclerodermiform porphyria cutanea tarda after torasemide. (26693635)
2015
14
A case of hypopituitarism and porphyria cutanea tarda in relation to estrogen therapy in a patient with empty sella syndrome. (25572312)
2015
15
Sclerodermoid lesions in a patient with multiple transplants and porphyria cutanea tarda. (26158360)
2015
16
Porphyria cutanea tarda and Sjogren's syndrome. (25054769)
2014
17
Hepatitis C- and HIV-induced porphyria cutanea tarda. (24470839)
2014
18
Porphyria cutanea tarda in a human immunodeficiency virus-infected patient: A rare scenario in India. (24958988)
2014
19
Treatment of chronic hepatitis with boceprevir leads to remission of porphyria cutanea tarda. (25154788)
2014
20
Sporadic porphyria cutanea tarda: treatment with chloroquine decreases hyperglycemia and reduces development of metabolic syndrome. (24630799)
2014
21
Ocular manifestations in porphyria cutanea tarda. (24811555)
2014
22
Porphyria cutanea tarda in a child following multi-agent chemotherapy. (24719070)
2014
23
A skin disease, a blood disease or something in between? An exploratory focus group study of patients' experiences with porphyria cutanea tarda. (24958197)
2014
24
Desferrioxamine treatment of porphyria cutanea tarda in a patient with HIV and chronic renal failure. (24502304)
2014
25
Boston keratoprosthesis for visual rehabilitation in porphyria cutanea tarda. (23378551)
2013
26
Familial porphyria cutanea tarda in Spain: characterization of eight novel mutations in the UROD gene and haplotype analysis of the common p.G281E mutation. (23545314)
2013
27
Images in clinical medicine. Porphyria cutanea tarda and hypertrichosis. (24088095)
2013
28
Precipitating factors of porphyria cutanea tarda in Brazil with emphasis on hemochromatosis gene (HFE) mutations. Study of 60 patients. (24068123)
2013
29
Risk factors for porphyria cutanea tarda -the iron/HFE connection. (23121614)
2013
30
Iron homeostasis in porphyria cutanea tarda: mutation analysis of promoter regions of CP, CYBRD1, HAMP and SLC40A1. (23012398)
2013
31
Is non-alcoholic steatohepatitis a predisposing factor to porphyria cutanea tarda? (23458397)
2013
32
Porphyria cutanea tarda and spherocytosis: a non-random association? (23093332)
2013
33
Dermacase. Can you identify this condition? Porphyria cutanea tarda. (23851543)
2013
34
Porphyria cutanea tarda in a hemodialysis patient with hepatitis C virus: efficacy of treatment with multiple phlebotomies and erythropoietin. (23354206)
2013
35
Increased serum hepcidin levels in patients with porphyria cutanea tarda. (22429447)
2013
36
Sporadic Porphyria Cutanea Tarda in a Patient with Multiple Sclerosis Treated with Interferon Beta 1-a Therapy: A Case Report. (23894244)
2013
37
Cascade testing of primary care blood samples with hyperferritinaemia identifies subjects with iron overload and porphyria cutanea tarda. (24081184)
2013
38
Co-existence of hereditary coproporphyria and porphyria cutanea tarda: The importance of genetic testing. (23582006)
2013
39
Porphyria cutanea tarda in a hemodialysis patient. (22753666)
2013
40
Non-classical congenital adrenal hyperplasia in association with porphyria cutanea tarda: co-incidence or trigger? (22783026)
2012
41
Hepatitis C, porphyria cutanea tarda and liver iron: an update. (22510500)
2012
42
Porphyria cutanea tarda in the Basque Country: significance of HFE gene mutations and of external factors. (22680055)
2012
43
Increased photosensitivity? Case report of porphyria cutanea tarda associated with systemic lupus erythematosus. (23223706)
2012
44
Deferasirox for porphyria cutanea tarda: a pilot study. (22911183)
2012
45
Porphyria cutanea tarda in an HCV-positive liver transplant patient: a case report. (23109461)
2012
46
Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda. (22985607)
2012
47
Porphyria cutanea tarda: treatment options revisited. (22982098)
2012
48
Comprehensive cytochrome P450 CYP1A2 gene analysis in French caucasian patients with familial and sporadic porphyria cutanea tarda. (21929532)
2012
49
Molecular analysis of the UROD gene in 17 Argentinean patients with familial porphyria cutanea tarda: characterization of four novel mutations. (22382040)
2012
50
Porphyria cutanea tarda with multiple nodular foci in the liver. (22115986)
2012

Variations for Porphyria Cutanea Tarda

About this section

UniProtKB/Swiss-Prot genetic disease variations for Porphyria Cutanea Tarda:

70 (show all 36)
id Symbol AA change Variation ID SNP ID
1URODp.Glu167LysVAR_007714rs121918058
2URODp.Gly281GluVAR_007715rs121918057
3URODp.Gly281ValVAR_007716rs121918057
4URODp.Arg292GlyVAR_007717rs121918059
5URODp.Ala80GlyVAR_007910rs776907084
6URODp.Met165ArgVAR_007911rs121918063
7URODp.Leu195PheVAR_007912rs121918064
8URODp.Leu253GlnVAR_007913rs36033115
9URODp.Asn304LysVAR_007914rs121918065
10URODp.Gly318ArgVAR_007915rs116233118
11URODp.Arg332HisVAR_007916rs121918066
12URODp.Ile334ThrVAR_007917
13URODp.Pro62LeuVAR_009103rs121918060
14URODp.Val134GlnVAR_009104
15URODp.His220ProVAR_009105
16URODp.Phe229LeuVAR_009106
17URODp.Tyr311CysVAR_009107rs121918061
18URODp.Met324ThrVAR_009108
19URODp.Arg142GlnVAR_010985
20URODp.Leu161GlnVAR_010986
21URODp.Ser219PheVAR_010987
22URODp.Pro235SerVAR_010988rs141312224
23URODp.Gly25GluVAR_022567rs764268015
24URODp.Phe46LeuVAR_022568rs769378741
25URODp.Ala80SerVAR_022569rs376921379
26URODp.Arg144ProVAR_022570
27URODp.Gly156AspVAR_022571rs762617943
28URODp.Arg193ProVAR_022572
29URODp.Leu216GlnVAR_022573
30URODp.Glu218LysVAR_022574
31URODp.Phe232LeuVAR_022575
32URODp.Ile260ThrVAR_022576
33URODp.Leu282ArgVAR_022577
34URODp.Gly303SerVAR_022578
35URODp.Gly168ArgVAR_065558
36URODp.Gly170AspVAR_065559

Clinvar genetic disease variations for Porphyria Cutanea Tarda:

5 (show all 11)
id Gene Variation Type Significance SNP ID Assembly Location
1URODNM_000374.4(UROD): c.578G> C (p.Arg193Pro)SNVPathogenicrs143823335GRCh37Chr 1, 45479684: 45479684
2URODNM_000374.4(UROD): c.6_15delAGCGAATGGG (p.Glu2Aspfs)deletionPathogenicrs397514764GRCh37Chr 1, 45477943: 45477952
3URODNM_000374.4(UROD): c.346C> T (p.Gln116Ter)SNVPathogenicrs397514765GRCh37Chr 1, 45479335: 45479335
4URODNM_000374.4(UROD): c.842G> T (p.Gly281Val)SNVPathogenicrs121918057GRCh37Chr 1, 45480475: 45480475
5URODNM_000374.4(UROD): c.842G> A (p.Gly281Glu)SNVPathogenicrs121918057GRCh37Chr 1, 45480475: 45480475
6URODNM_000374.4(UROD): c.636+1G> CSNVPathogenicrs145195562GRCh38Chr 1, 45014071: 45014071
7URODNM_000374.4(UROD): c.942G> A (p.Glu314=)SNVPathogenicrs121918062GRCh37Chr 1, 45480678: 45480678
8URODNM_000374.4(UROD): c.494T> G (p.Met165Arg)SNVPathogenicrs121918063GRCh37Chr 1, 45479600: 45479600
9URODNM_000374.4(UROD): c.583C> T (p.Leu195Phe)SNVPathogenicrs121918064GRCh37Chr 1, 45479689: 45479689
10URODNM_000374.4(UROD): c.912C> A (p.Asn304Lys)SNVPathogenicrs121918065GRCh37Chr 1, 45480648: 45480648
11URODNM_000374.4(UROD): c.995G> A (p.Arg332His)SNVPathogenicrs121918066GRCh37Chr 1, 45481061: 45481061

Expression for genes affiliated with Porphyria Cutanea Tarda

About this section
Search GEO for disease gene expression data for Porphyria Cutanea Tarda.

Pathways for genes affiliated with Porphyria Cutanea Tarda

About this section

GO Terms for genes affiliated with Porphyria Cutanea Tarda

About this section

Cellular components related to Porphyria Cutanea Tarda according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1basal part of cellGO:004517810.5HFE, TF
2HFE-transferrin receptor complexGO:19907129.2HFE, HFE2, TF, TFRC
3recycling endosomeGO:00550379.2HFE, TF, TFRC
4extracellular spaceGO:00056158.1ALAD, HAMP, HFE, HFE2, TF, TFRC

Biological processes related to Porphyria Cutanea Tarda according to GeneCards Suite gene sharing:

(show all 34)
idNameGO IDScoreTop Affiliating Genes
1cellular response to lead ionGO:007128410.6ALAD, HMBS
2response to amino acidGO:004320010.5ALAD, HMBS
3response to cobalt ionGO:003202510.5ALAD, HMBS
4cellular response to iron ionGO:007128110.5HFE, TF
5positive regulation of receptor-mediated endocytosisGO:004826010.5HFE, TF
6response to mercury ionGO:004668910.5ALAD, UROD
7response to inorganic substanceGO:001003510.5ALAD, CPOX
8protoporphyrinogen IX metabolic processGO:004650110.4FECH, PPOX
9cellular response to dexamethasone stimulusGO:007154910.4FECH, HMBS
10response to vitaminGO:003327310.3ALAD, HMBS
11porphyrin-containing compound biosynthetic processGO:000677910.3PPOX, UROS
12cellular response to amine stimulusGO:007141810.3HMBS, UROS
13response to insecticideGO:001708510.3CPOX, FECH
14response to metal ionGO:001003810.2ALAD, FECH
15response to platinum ionGO:007054110.2ALAD, FECH
16response to estradiolGO:003235510.1CYP1A2, HMBS, UROD
17response to arsenic-containing substanceGO:004668510.1ALAD, CPOX, FECH
18liver regenerationGO:009742110.1HAMP, HFE
19multicellular organismal iron ion homeostasisGO:006058610.1HAMP, HFE
20cellular response to arsenic-containing substanceGO:007124310.1HMBS, UROD, UROS
21iron ion homeostasisGO:005507210.0HFE, HFE2, TF
22response to lead ionGO:001028810.0ALAD, CPOX, FECH
23response to iron ion starvationGO:19906419.9HAMP, HFE
24response to hypoxiaGO:00016669.8ALAD, HMBS, TFRC
25acute-phase responseGO:00069539.5HAMP, HFE, TFRC
26transferrin transportGO:00335729.4TF, TFRC
27response to zinc ionGO:00100439.4ALAD, HAMP, HMBS
28response to drugGO:00424939.4ALAD, CYP1A2, FECH, HMBS, PPOX
29response to methylmercuryGO:00515979.3ALAD, CPOX, FECH, HMBS, UROD
30response to ethanolGO:00454719.3ALAD, FECH, HAMP, UROD
31protoporphyrinogen IX biosynthetic processGO:00067829.1ALAD, CPOX, HMBS, PPOX, UROD, UROS
32heme biosynthetic processGO:00067838.7ALAD, CPOX, FECH, HMBS, PPOX, UROD
33cellular iron ion homeostasisGO:00068798.5HAMP, HFE, HFE2, TF, TFRC
34response to iron ionGO:00100398.5ALAD, CPOX, HAMP, HFE, TFRC, UROD

Molecular functions related to Porphyria Cutanea Tarda according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1uroporphyrinogen-III synthase activityGO:00048529.6HMBS, UROS
2ferrous iron bindingGO:00081989.6FECH, TF, UROD
3transferrin receptor bindingGO:19904599.0HFE, HFE2, TF

Sources for Porphyria Cutanea Tarda

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet